Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
1.500
-0.040 (-2.60%)
May 13, 2025, 9:42 AM - Market open
Company Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors.
The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.
Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Editas Medicine, Inc.
| Country | United States |
| Founded | 2013 |
| IPO Date | Feb 3, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 246 |
| CEO | Gilmore O’Neill |
Contact Details
Address: 11 Hurley Street Cambridge, Massachusetts 02141 United States | |
| Phone | 617 401 9000 |
| Website | editasmedicine.com |
Stock Details
| Ticker Symbol | EDIT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001650664 |
| CUSIP Number | 28106W103 |
| ISIN Number | US28106W1036 |
| Employer ID | 46-4097528 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gilmore O'Neill M.D. | President, Chief Executive Officer and Director |
| Dr. Feng Zhang Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. George McDonald Church Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Amy Parison | Senior Vice President and Chief Financial Officer |
| Gregory Whitehead | Executive Vice President and Chief Technical and Quality Officer |
| Dr. Linda C. Burkly Ph.D. | Executive Vice President and Chief Scientific Officer |
| Linea Aspesi | Executive Vice President and Chief Administration Officer |
| Cristi Barnett | Senior Vice President of Corporate Communications and Investor Relations |
| Damien Grierson J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Frank Panaccio | Senior Vice President and Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2025 | 8-K | Current Report |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Apr 15, 2025 | ARS | Filing |
| Apr 15, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 15, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 21, 2025 | EFFECT | Notice of Effectiveness |
| Mar 20, 2025 | 8-K | Current Report |